GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ningbo Menovo Pharmaceutical Co Ltd (SHSE:603538) » Definitions » ROIC %

Ningbo Menovo Pharmaceutical Co (SHSE:603538) ROIC % : 2.73% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ningbo Menovo Pharmaceutical Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Ningbo Menovo Pharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 2.73%.

As of today (2024-05-29), Ningbo Menovo Pharmaceutical Co's WACC % is 4.07%. Ningbo Menovo Pharmaceutical Co's ROIC % is 1.36% (calculated using TTM income statement data). Ningbo Menovo Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Ningbo Menovo Pharmaceutical Co ROIC % Historical Data

The historical data trend for Ningbo Menovo Pharmaceutical Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ningbo Menovo Pharmaceutical Co ROIC % Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.35 6.50 5.92 7.59 5.19

Ningbo Menovo Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 1.76 5.10 -0.69 2.73

Competitive Comparison of Ningbo Menovo Pharmaceutical Co's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ningbo Menovo Pharmaceutical Co's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's ROIC % falls into.



Ningbo Menovo Pharmaceutical Co ROIC % Calculation

Ningbo Menovo Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=84.387 * ( 1 - -103.36% )/( (3232.249 + 3385.574)/ 2 )
=171.6094032/3308.9115
=5.19 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4419.493 - 655.081 - ( 1009.321 - max(0, 1362.219 - 1894.382+1009.321))
=3232.249

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4423.516 - 656.834 - ( 724.689 - max(0, 1378.267 - 1759.375+724.689))
=3385.574

Ningbo Menovo Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=119.772 * ( 1 - 22.77% )/( (3385.574 + 3384.815)/ 2 )
=92.4999156/3385.1945
=2.73 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4423.516 - 656.834 - ( 724.689 - max(0, 1378.267 - 1759.375+724.689))
=3385.574

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4344.246 - 567.251 - ( 617.189 - max(0, 1295.755 - 1687.935+617.189))
=3384.815

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ningbo Menovo Pharmaceutical Co  (SHSE:603538) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Ningbo Menovo Pharmaceutical Co's WACC % is 4.07%. Ningbo Menovo Pharmaceutical Co's ROIC % is 1.36% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Ningbo Menovo Pharmaceutical Co ROIC % Related Terms

Thank you for viewing the detailed overview of Ningbo Menovo Pharmaceutical Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ningbo Menovo Pharmaceutical Co (SHSE:603538) Business Description

Traded in Other Exchanges
N/A
Address
No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
Executives
Xu Jian senior management
Cao Qian Director
Yao Fang Director
Ying Gao Feng Director
Sun Yan Director
Shi Jian Xiang Director
Wu Feng Yun Director
Tu Ying Director
Yao Cheng Zhi Director
Zheng Hui Lin Supervisors
Jiao Hua senior management

Ningbo Menovo Pharmaceutical Co (SHSE:603538) Headlines

No Headlines